Adrenergic Drug Market Size & Share, by Drug Class (Vasopressors, Bronchodilators, Catecholamine); Route of Administration (Intravenous Route, Oral Route, Inhalation); Disease Indication (Bronchitis, Cardiac Arrest, Shock, Chronic Obstructive Pulmonary Disease); Distribution Channel (Retail Pharmacy, Hospital Pharmacy, E-Commerce) - Global Supply & Demand Analysis, Growth Forecasts, Statistics Report 2024-2036

  • Report ID: 2541
  • Published Date: Nov 24, 2023
  • Report Format: PDF, PPT

Companies Dominating the Adrenergic Drug Market

top-features-companies
    • Pfizer, Inc.
      • Company Overview
      • Business Strategy
      • Key Product Offerings
      • Financial Performance
      • Key Performance Indicators
      • Risk Analysis
      • Recent Development
      • Regional Presence
      • SWOT Analysis
    • Novartis AG
    • GSK plc.
    • AstraZeneca
    • Merck & Co., Inc.
    • Sanofi
    • Johnson & Johnson, Inc.
    • Eli Lilly and Company
    • F. Hoffmann-La Roche Ltd
    • Viatris Inc.

Browse Key Market Insights with Data Illustration:

In-the-news

In The News

  • January 11, 2023: The FDA has authorized Airsupra, an inhalation aerosol containing albuterol and budesonide, for the treatment or prevention of bronchoconstriction as needed, as well as to lower the risk of asthma attacks in individuals with asthma who are 18 years of age or older. The medication known as Airsupra is a combination of the beta-2 adrenergic agonist albuterol and the corticosteroid budesonide. It is the first short-acting beta-agonist and inhaled corticosteroid (ICS) combo to be approved in the United States. Furthermore, Airsupra is the first ICS-containing medicine approved in the United States for use as an asthma relief (as opposed to a controller).
  • September 27, 2023: Global healthcare leader Viatris Inc. and clinical-stage ophthalmic biopharmaceutical company Ocuphire Pharma, Inc., which develops and markets small-molecule therapies for the treatment of retinal and refractive eye disorders, announced that the FDA in the United States has approved RYZUMVI (phentolamine ophthalmic solution) 0.75% for the treatment of pharmacologically-induced mydriasis caused by parasympatholytic (like tropicamide) or adrenergic agonists (like phenylephrine).  

Author Credits:  Radhika Gupta, Shivam Bhutani


  • Report ID: 2541
  • Published Date: Nov 24, 2023
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

The major factors driving the growth of the market are surge in prevalence of cardiovascular disease, rising geriatric population, and growing research & development for the launch of new products.

The market size of adrenergic drug is anticipated to attain a CAGR of ~6% over the forecast period, i.e., 2024-2036.

The major players in the market are Pfizer, Inc., Novartis AG, GSK plc., AstraZeneca, and others.

The bronchodilators segment is anticipated to garner the largest market size by the end of 2036 and display significant growth opportunities.

The market in the North America region is projected to hold the largest market share by the end of 2036 and provide more business opportunities in the future.
Inquiry Before Buying Request Free Sample
  GET A FREE SAMPLE

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying